The University of Texas MD Anderson Cancer Center (US)
Access 250+ million papers and cite this researcher's work with AI assistance
H-index
232
Publications
5578
Citations
270178
i10-index
2523
Want to find and read papers by this researcher? AnswerThis gives you instant access.
Sign Up Free| Title | Year | Citations |
|---|---|---|
Efficacy and Safety of a Specific Inhibitor of the... | 2001 | 5241 |
The 5th edition of the World Health Organization C... | 2022 | 3897 |
Imatinib Compared with Interferon and Low-Dose Cyt... | 2003 | 3564 |
Five-Year Follow-up of Patients Receiving Imatinib... | 2006 | 3480 |
Revised International Prognostic Scoring System fo... | 2012 | 3139 |
Activity of a Specific Inhibitor of the BCR-ABL Ty... | 2001 | 2722 |
A Double-Blind, Placebo-Controlled Trial of Ruxoli... | 2012 | 2050 |
European LeukemiaNet recommendations for the manag... | 2013 | 1988 |
Venetoclax combined with decitabine or azacitidine... | 2018 | 1852 |
Dasatinib in Imatinib-Resistant Philadelphia Chrom... | 2006 | 1772 |
Hagop M. Kantarjian is a researcher with 5578 publications and 270178 citations. They are affiliated with The University of Texas MD Anderson Cancer Center. Their research focuses on . With an h-index of 232, they are among the top researchers in their field.
Distribution of citations across publications
AnswerThis uses AI to help you search, understand, and cite research from Hagop M. Kantarjian and 250M+ other papers.
Citations per publication by year